{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:41:20Z","timestamp":1793130080949,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41591-024-02813-1","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T06:01:41Z","timestamp":1709532101000},"page":"1035-1043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7668-9674","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7105-3052","authenticated-orcid":false,"given":"Ying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6312-9299","authenticated-orcid":false,"given":"Hui-Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9849-347X","authenticated-orcid":false,"given":"Wei-Jia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Long","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Zhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Shen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-3134","authenticated-orcid":false,"given":"Wen-Ting","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-4453","authenticated-orcid":false,"given":"Lin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-6145","authenticated-orcid":false,"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"2813_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.eng.2020.10.017","volume":"7","author":"Z-X Wang","year":"2021","unstructured":"Wang, Z.-X. et al. Temporal change in treatment patterns of metastatic colorectal cancer and its association with patient survival: a retrospective cohort study based on an intelligent big-data platform. Engineering 7, 526\u2013533 (2021).","journal-title":"Engineering"},{"key":"2813_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr.","year":"2022","unstructured":"Diaz, L. A. Jr. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659\u2013670 (2022).","journal-title":"Lancet Oncol."},{"key":"2813_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz, H. J. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J. Clin. Oncol. 40, 161\u2013170 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2813_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","volume":"8","author":"G Chen","year":"2023","unstructured":"Chen, G. et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol. Hepatol. 8, 422\u2013431 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2813_CR5","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2813_CR6","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","volume":"5","author":"F Wang","year":"2019","unstructured":"Wang, F. et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 5, 1504\u20131506 (2019).","journal-title":"JAMA Oncol."},{"key":"2813_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.524","volume":"11","author":"YX Chen","year":"2021","unstructured":"Chen, Y. X. et al. POLE\/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. Clin. Transl. Med 11, e524 (2021).","journal-title":"Clin. Transl. Med"},{"key":"2813_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/cac2.12095","volume":"40","author":"F Wang","year":"2020","unstructured":"Wang, F. et al. Expert opinions on immunotherapy for patients with colorectal cancer. Cancer Commun. (Lond.) 40, 467\u2013472 (2020).","journal-title":"Cancer Commun. (Lond.)"},{"key":"2813_CR9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/cac2.12199","volume":"41","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis. Cancer Commun. (Lond.) 41, 921\u2013924 (2021).","journal-title":"Cancer Commun. (Lond.)"},{"key":"2813_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","volume":"20","author":"RR Ramjiawan","year":"2017","unstructured":"Ramjiawan, R. R., Griffioen, A. W. & Duda, D. G. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis 20, 185\u2013204 (2017).","journal-title":"Angiogenesis"},{"key":"2813_CR11","first-page":"2514","volume":"6","author":"S Du Four","year":"2016","unstructured":"Du Four, S. et al. Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. Am. J. Cancer Res 6, 2514\u20132531 (2016).","journal-title":"Am. J. Cancer Res"},{"key":"2813_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi, M. et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer 18, 60 (2019).","journal-title":"Mol. Cancer"},{"key":"2813_CR13","doi-asserted-by":"publisher","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel, M. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med. 9, eaak9670 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2813_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron, T. et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 212, 139\u2013148 (2015).","journal-title":"J. Exp. Med."},{"key":"2813_CR15","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka, S. et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053\u20132061 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2813_CR16","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.1016\/j.eclinm.2023.101917","volume":"58","author":"M Fakih","year":"2023","unstructured":"Fakih, M. et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine 58, 101917 (2023).","journal-title":"EClinicalMedicine"},{"key":"2813_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2022.03.026","volume":"169","author":"RD Kim","year":"2022","unstructured":"Kim, R. D. et al. A phase I\/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur. J. Cancer 169, 93\u2013102 (2022).","journal-title":"Eur. J. Cancer"},{"key":"2813_CR18","doi-asserted-by":"publisher","first-page":"100383","DOI":"10.1016\/j.xcrm.2021.100383","volume":"2","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis. Cell Rep. Med 2, 100383 (2021).","journal-title":"Cell Rep. Med"},{"key":"2813_CR19","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/1078-0432.CCR-20-3416","volume":"27","author":"S Cousin","year":"2021","unstructured":"Cousin, S. et al. Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial. Clin. Cancer Res. 27, 2139\u20132147 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2813_CR20","doi-asserted-by":"publisher","first-page":"7390","DOI":"10.18632\/oncotarget.7180","volume":"7","author":"SR Gameiro","year":"2016","unstructured":"Gameiro, S. R., Malamas, A. S., Tsang, K. Y., Ferrone, S. & Hodge, J. W. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget 7, 7390\u20137402 (2016).","journal-title":"Oncotarget"},{"key":"2813_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2019.12.019","volume":"65","author":"S Gomez","year":"2020","unstructured":"Gomez, S., Tabernacki, T., Kobyra, J., Roberts, P. & Chiappinelli, K. B. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol. 65, 99\u2013113 (2020).","journal-title":"Semin Cancer Biol."},{"key":"2813_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/cancers14010066","volume":"14","author":"E Borcoman","year":"2021","unstructured":"Borcoman, E. et al. HDAC inhibition to prime immune checkpoint inhibitors. Cancers (Basel) 14, 66 (2021).","journal-title":"Cancers (Basel)"},{"key":"2813_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell 11, 472\u2013482 (2020).","journal-title":"Protein Cell"},{"key":"2813_CR24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aae0491","volume":"354","author":"DR Sen","year":"2016","unstructured":"Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 1165\u20131169 (2016).","journal-title":"Science"},{"key":"2813_CR25","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1200\/JCO.2018.36.15_suppl.3557","volume":"36","author":"NS Azad","year":"2018","unstructured":"Azad, N. S. et al. ENCORE 601: a phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer. J. Clin. Oncol. 36, 3557 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2813_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-20-3305","volume":"27","author":"MD Hellmann","year":"2021","unstructured":"Hellmann, M. D. et al. Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy. Clin. Cancer Res. 27, 1019\u20131028 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2813_CR27","doi-asserted-by":"publisher","first-page":"CT072","DOI":"10.1158\/1538-7445.AM2019-CT072","volume":"79","author":"RJ Sullivan","year":"2019","unstructured":"Sullivan, R. J. et al. Abstract CT072: efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy. Cancer Res. 79, CT072 (2019).","journal-title":"Cancer Res."},{"key":"2813_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-134665","volume":"136","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Anti-PD-1 antibody (Sintilimab) plus histone deacetylase inhibitor (chidamide) for the treatment of refractory or relapsed extranodal natural killer\/T cell lymphoma, nasal type (r\/r-ENKTL): preliminary results from a prospective, multicenter, single-arm, phase Ib\/II trial (SCENT). Blood 136, 39\u201340 (2020).","journal-title":"Blood"},{"key":"2813_CR29","doi-asserted-by":"publisher","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","volume":"25","author":"JE Gray","year":"2019","unstructured":"Gray, J. E. et al. Phase I\/Ib study of pembrolizumab plus vorinostat in advanced\/metastatic non-small cell lung cancer. Clin. Cancer Res. 25, 6623\u20136632 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2813_CR30","doi-asserted-by":"publisher","first-page":"S479","DOI":"10.1016\/j.annonc.2021.08.550","volume":"32","author":"A Sonnenblick","year":"2021","unstructured":"Sonnenblick, A. et al. 267P Phase Ib\/II open-label, randomized evaluation of second- or third-line (2L\/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC). Ann. Oncol. 32, S479 (2021).","journal-title":"Ann. Oncol."},{"key":"2813_CR31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1200\/JCO.2020.38.15_suppl.1014","volume":"38","author":"J O\u2019Shaughnessy","year":"2020","unstructured":"O\u2019Shaughnessy, J. et al. Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC). J. Clin. Oncol. 38, 1014 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2813_CR32","doi-asserted-by":"publisher","first-page":"S555","DOI":"10.1016\/j.annonc.2021.08.964","volume":"32","author":"E Cartwright","year":"2021","unstructured":"Cartwright, E. et al. 443P EMERGE: a phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers-phase IIA dose finding. Ann. Oncol. 32, S555\u2013S556 (2021).","journal-title":"Ann. Oncol."},{"key":"2813_CR33","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/j.esmoop.2022.100594","volume":"7","author":"MP Saunders","year":"2022","unstructured":"Saunders, M. P. et al. CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial. ESMO open 7, 100594 (2022).","journal-title":"ESMO open"},{"key":"2813_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01485-x","volume":"15","author":"M Baretti","year":"2023","unstructured":"Baretti, M. et al. A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer. Clin. Epigenetics 15, 74 (2023).","journal-title":"Clin. Epigenetics"},{"key":"2813_CR35","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li, J. et al. Effect of fruquintinib versus placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA 319, 2486\u20132496 (2018).","journal-title":"JAMA"},{"key":"2813_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303\u2013312 (2013).","journal-title":"Lancet"},{"key":"2813_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA Study. J. Clin. Oncol. 36, 350\u2013358 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2813_CR38","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2813_CR39","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.7150\/jca.44622","volume":"11","author":"YD Kim","year":"2020","unstructured":"Kim, Y. D. et al. HDAC inhibitor, CG-745, enhances the anti-cancer effect of anti-PD-1 immune checkpoint inhibitor by modulation of the immune microenvironment. J. Cancer 11, 4059\u20134072 (2020).","journal-title":"J. Cancer"},{"key":"2813_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02598-5","volume":"20","author":"P Zhang","year":"2022","unstructured":"Zhang, P. et al. Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Med 20, 435 (2022).","journal-title":"BMC Med"},{"key":"2813_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang, Y. et al. Improving immune-vascular crosstalk for cancer immunotherapy. Nat. Rev. Immunol. 18, 195\u2013203 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2813_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","volume":"181","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: the dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. Eur. J. Cancer 181, 26\u201337 (2023).","journal-title":"Eur. J. Cancer"},{"key":"2813_CR43","doi-asserted-by":"publisher","first-page":"S728","DOI":"10.1016\/j.annonc.2022.07.561","volume":"33","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. 423P fruquintinib plus sintilimab in refractory repair-proficient (pMMR)\/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): preliminary clinical results and biomarker analyses from a phase II study. Ann. Oncol. 33, S728 (2022).","journal-title":"Ann. Oncol."},{"key":"2813_CR44","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","volume":"9","author":"M Fakih","year":"2023","unstructured":"Fakih, M. et al. Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial. JAMA Oncol. 9, 627\u2013634 (2023).","journal-title":"JAMA Oncol."},{"key":"2813_CR45","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-021-00247-z","volume":"2","author":"PMK Westcott","year":"2021","unstructured":"Westcott, P. M. K. et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat. Cancer 2, 1071\u20131085 (2021).","journal-title":"Nat. Cancer"},{"key":"2813_CR46","doi-asserted-by":"publisher","first-page":"1039631","DOI":"10.3389\/fimmu.2022.1039631","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer. Front Immunol. 13, 1039631 (2022).","journal-title":"Front Immunol."},{"key":"2813_CR47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2019.37.4_suppl.591","volume":"37","author":"AG Murphy","year":"2019","unstructured":"Murphy, A. G. et al. Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer. J. Clin. Oncol. 37, 591 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2813_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/JTO.0000000000000071","volume":"9","author":"RS Heist","year":"2014","unstructured":"Heist, R. S. et al. CALGB 30704 (Alliance): a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J. Thorac. Oncol. 9, 214\u2013221 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"2813_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/neuonc\/noac144","volume":"25","author":"JM Perez-Garcia","year":"2023","unstructured":"Perez-Garcia, J. M. et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 25, 157\u2013166 (2023).","journal-title":"Neuro Oncol."},{"key":"2813_CR50","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki, Y. et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol. 18, 1172\u20131181 (2017).","journal-title":"Lancet Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02813-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02813-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02813-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T08:03:38Z","timestamp":1713513818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02813-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2813"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-02813-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"30 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.H.X. has served as a consulting or advisory role for Bristol-Myers Squibb, Merck Serono, Roche, Astellas, and AstraZeneca. The remaining authors delcare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}